Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Yury Gadayev

Physician Assistant Centennial, CO Physician Assistant

NPI 1841371796 CMS profile 10791809

6801 S Yosemite St, Centennial, CO 80112

Open in the dashboard

General payments

$18,063

799 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yury Gadayev of Centennial, CO is reported in the CMS Open Payments database as having received $18,063 across 799 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,191 179
2024 General $2,945 125
2023 General $2,539 108
2022 General $3,688 194
2021 General $4,700 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yury Gadayev
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Yury Gadayev were reported at $4,191. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Yury Gadayev Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $4,700 $132 $37–$438 $132
2022 $3,688 $155 $48–$522 $149
2023 $2,539 $167 $52–$557 $160
2024 $2,945 $178 $55–$600 $164
2025 $4,191 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,849 109 payments
  2. Pfizer Inc. $1,305 86 payments
  3. Genzyme Corporation $1,102 29 payments
  4. Argenx US, Inc. $902 39 payments
  5. Neurocrine Biosciences, Inc. $789 18 payments
  6. Lilly USA, LLC $752 25 payments
  7. Biogen, Inc. $715 25 payments
  8. Novartis Pharmaceuticals Corporation $710 51 payments
  9. EMD Serono, Inc. $658 23 payments
  10. Lundbeck LLC $622 21 payments
  11. Other $8,660 373 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,670 794 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $280 3 payments
  3. Education $114 2 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $1,232 77 payments
  2. AUBAGIO $908 26 payments
  3. VYVGART Hytrulo $902 39 payments
  4. UBRELVY $801 42 payments
  5. NURTEC ODT Primary Care $752 25 payments
  6. ZAVZPRET $646 47 payments
  7. PANZYGA $623 36 payments
  8. NURTEC ODT Pain $592 49 payments
  9. VUMERITY $489 19 payments
  10. KISUNLA $481 9 payments
  11. Other $11,680 534 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,010

Median for Physician Assistant: 241

Drug cost

$217,925

Median for Physician Assistant: $4,110

Branded share of claims

17.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 18 $107,345
Nurtec Odt Rimegepant Sulfate Brand 17 $32,746
Emgality Pen Galcanezumab-Gnlm Brand 32 $24,232
Botox Onabotulinumtoxina Brand 12 $17,893
Aimovig Autoinjector Erenumab-Aooe Brand 12 $9,294
Rivastigmine Generic 32 $4,663
Lidocaine Generic 14 $4,371
Sumatriptan Succinate Generic 15 $3,041
Memantine Hcl Generic 57 $1,900
Gabapentin Generic 106 $1,835

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$46,922

Of which drugs: $17,520

Medicare patients

94

Average age 67

Services billed

3,907

66 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 68%
High blood pressure 61%
Depression 39%
Diabetes 24%
Ischemic heart disease 22%
COPD 22%
Osteoporosis 21%
Alzheimer's or dementia 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 12 207 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$434 — —
VYVGART Hytrulo
$333 — —
INGREZZA
$296 — —
KESIMPTA
$217 — —
UBRELVY
$200 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

799 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record